UBS Group Increases Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,099.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective increased by equities researchers at UBS Group from $1,090.00 to $1,099.00 in a research report issued on Wednesday, Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. UBS Group’s price target suggests a potential upside of 21.95% from the company’s previous close.

REGN has been the subject of several other reports. StockNews.com upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, April 12th. Cantor Fitzgerald reissued a “neutral” rating and set a $925.00 target price on shares of Regeneron Pharmaceuticals in a research report on Monday. Morgan Stanley lifted their target price on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 13th. Barclays raised their price target on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 23rd. Finally, Truist Financial reissued a “buy” rating and set a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. One research analyst has rated the stock with a sell rating, four have given a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $976.41.

Regeneron Pharmaceuticals Stock Up 0.8 %

Shares of REGN opened at $901.19 on Wednesday. Regeneron Pharmaceuticals has a 52 week low of $684.80 and a 52 week high of $998.33. The stock has a market capitalization of $98.91 billion, a price-to-earnings ratio of 25.93, a PEG ratio of 2.58 and a beta of 0.11. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69. The stock has a fifty day moving average of $955.19 and a 200-day moving average of $890.52.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. The business had revenue of $3.43 billion during the quarter, compared to the consensus estimate of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. Regeneron Pharmaceuticals’s quarterly revenue was up .6% on a year-over-year basis. During the same period in the prior year, the business posted $10.96 earnings per share. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals will post 38.58 earnings per share for the current fiscal year.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, March 1st. The shares were sold at an average price of $982.05, for a total value of $98,205.00. Following the sale, the director now directly owns 18,282 shares in the company, valued at approximately $17,953,838.10. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the business’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the sale, the executive vice president now directly owns 48,306 shares of the company’s stock, valued at approximately $46,203,239.82. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $982.05, for a total transaction of $98,205.00. Following the completion of the sale, the director now directly owns 18,282 shares of the company’s stock, valued at approximately $17,953,838.10. The disclosure for this sale can be found here. In the last quarter, insiders have sold 13,729 shares of company stock worth $13,124,641. 8.83% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. SteelPeak Wealth LLC purchased a new stake in Regeneron Pharmaceuticals during the first quarter worth $385,000. River Street Advisors LLC increased its position in Regeneron Pharmaceuticals by 7.0% during the first quarter. River Street Advisors LLC now owns 460 shares of the biopharmaceutical company’s stock worth $443,000 after purchasing an additional 30 shares during the last quarter. New Mexico Educational Retirement Board increased its position in Regeneron Pharmaceuticals by 10.7% during the first quarter. New Mexico Educational Retirement Board now owns 6,200 shares of the biopharmaceutical company’s stock worth $5,967,000 after purchasing an additional 600 shares during the last quarter. Burns J W & Co. Inc. NY acquired a new stake in shares of Regeneron Pharmaceuticals during the first quarter valued at about $1,001,000. Finally, Hennion & Walsh Asset Management Inc. increased its position in shares of Regeneron Pharmaceuticals by 22.0% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 2,365 shares of the biopharmaceutical company’s stock valued at $2,276,000 after acquiring an additional 426 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.